Reference Year Sample Sex Age (y) (E/C) Clinical stage (E/C) Pathology Experimental group (E) Control group (C) Period Outcome measure Chen et al. [13 ] 2005 60 (30/30) F: 25, M: 5/F: 21, M: 9 54 ± 4/59 ± 2 III: 21, IV: 9/III: 17, IV: 13 S22, A8/S19, A11 Rg3 20 mg po. Bid + C EP (VP-16 + DDP), MVP (MMC + VDS + DDP) 6–8 weeks Tumor response (UICC) Chen and Li [14 ] 2012 70 (35/35) F: 24, M: 11/F: 22, M: 13 55.5/60.5 (average age) III: 14, IV: 21/III: 13, IV: 22 S20, A15/S18, A17 Rg3 20 mg po. Bid + C GP (GEM + DDP) 6–9 weeks Tumor response (RECIST) Chen et al. [15 ] 2014 68 (34/34) M: 39, F: 29 41–73 (median age 55) III, IV S21, A26, AS18, L3 Rg3 20 mg po. Bid + C TP (PTX + DDP) 12 weeks Tumor response (RECIST) Du [16 ] 2014 60 (30/30) F: 31, M: 29 35–67 (average age 40.2 ± 3.6) IV Non-small cell cancer Rg3 20 mg po. Bid + C TP (PTX + DDP) 6 weeks Tumor response (RECIST) Li et al. [17 ] 2012 77 (39/38) Unclear Unclear IV S14, A23, L2/S16, A20, L2 Rg3 20 mg po. Bid + C GP (GEM + DDP) 6 weeks Tumor response (RECIST) Liu et al. [18 ] 2007 70 (35/35) F: 43, M: 27 35–70 (median age 56) IV S26, A40, L4 Rg3 20 mg po. Bid + C NP (NVB + DDP) 6 weeks Tumor response (WHO) Liu et al. [19 ] 2015 120 (60/60) F: 46, M: 14/F: 35, M: 25 34–71 (52.5 ± 2)/35–74 (54.6 ± 2.1) (average age) III: 37, IV: 23/III: 29, IV: 31 S41, A19/S46, A14 Rg3 20 mg po. Bid + C NP (NVB + DDP) 6 weeks Tumor response (unclear) Liu et al. [20 ] 2009 64 (34/30) F: 26, M: 8/F: 19, M: 11 43–75 (62)/31–66 (58) (median age) III: 22, IV: 12/III: 26, IV: 4 S9, A21, AS4/S6, A21, AS2 Rg3 20 mg po. Bid + C NP (NVB + DDP) 6 weeks Tumor response (WHO) Liu et al. [21 ] 2007 68 (35/33) F: 24, M: 11/F: 23, M: 10 65–75 (69)/65–75 (70) (median age) IIIb: 28, IV: 7/IIIb: 23, IV: 10 S18, A15, AS2/S17, A15, AS1 Rg3 20 mg po. Bid + C NP (NVB + DDP) 6 weeks Tumor response (WHO) Pang [22 ] 2012 43 (22/21) F: 13, M: 9/F: 13, M: 8 47–80 (average age 63.95) III: 13, IV: 30 A26, S18 Rg3 20 mg po. Bid + C GP, TP (DTX + DDP), PC (PEM + DDP) 6 weeks Tumor response (RECIST) Qi and Zhang [23 ] 2011 70 (35/35) M: 48, F: 22 Median age 57 IV S26, A40, L4 Rg3 20 mg po. Bid + C NP (NVB + DDP) 12 weeks Tumor response (unclear) Qin et al. [24 ] 2001 39 (23/16) F: 19, M: 4/F: 13, M: 3 Median age 59.6/57.2 III: 18, IV: 5/III: 12, IV: 4 S11, A8, AS4/S7, A6, AS3 Rg3 20 mg po. Bid + C EP (VP-16 + DDP) 8 weeks Tumor response (WHO) Shao [25 ] 2013 68 (33/35) F: 23, M: 10/F: 26, M: 9 65–80 (71 ± 4)/65–81 (72 ± 4) (average age) III: 26, IV: 7/III: 26, IV: 9 S15, A17, P1/S17, A16, P2 Rg3 20 mg po. Bid + C DTX 6 weeks Tumor response (unclear) Shi et al. [26 ] 2006 41 (22/19) F: 16, M: 6/F: 15, M: 4 45–75 (62)/37–64 (58) (median age) III: 5, IV: 17/III: 5, IV: 14 S9, A12, AS1/S4, A14, P1 Rg3 20 mg po. Bid + C NP (NVB + DDP), MVP (MMC + VDS + DDP) 24 weeks Tumor response (WHO) Sun et al. [27 ] 2006 115 (54/61) M: 40, F: 14/M: 39, F: 22 22–75 (62)/32–74 (62) (median age) III: 21, IV: 33/III: 24/IV: 37 S16, A27, AS6/S13, A44, AS2 Rg3 20 mg po. Bid + C NP (NVB + DDP) 6 weeks Tumor response (WHO) Tu [28 ] 2008 41 (21/20) M: 13, F: 8/M: 11, F: 9 36–75 (56.7) (average age) III: 7, IV: 14/III: 8, IV: 12 S7, A10, O4/S9, A9, O2 Rg3 20 mg po. Bid + C TP (PTX + DDP) At least 6 weeks Tumor response (RECIST) Wu et al. [29 ] 2014 40 (20/20) M: 11, F: 9/M: 11, F: 9 47–77 (60.6)/45–83 (62.2) (median age) III: 11, IV: 9/III: 11, IV: 9 S6, A12, AS2/S6, A13, AS1 Rg3 20 mg po. Bid + C GP/NP/TP 12–18 weeks Tumor response (RECIST) Yang et al. [30 ] 2014 29 (15/14) M: 11, F: 4/M: 10, F: 4 70–85 (76) (average age) III: 9, IV: 6/III: 7, IV: 7 S5, A9/S4, A10 Rg3 20 mg po. Bid + C S-1 12 weeks Tumor response (RECIST) Zhang et al. [31 ] 2006 72 (38/34) Unclear 53.2/51.9 (median age) III: 23, IV: 15/III: 21, IV: 13 S19, A15, AS4/S17, A14, AS3 Rg3 20 mg po. Bid + C CTX 12 weeks KPS Niu et al. [32 ] 2016 100 (56/44) M: 68, F: 32 38–72 (average age 53.12 ± 4.75) IV Non-small cell cancer Rg3 20 mg po. Bid + C PTX 12 weeks Tumor response (WHO)
